tiprankstipranks
Trending News
More News >
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH

Dianthus Therapeutics (DNTH) AI Stock Analysis

Compare
314 Followers

Top Page

DN

Dianthus Therapeutics

(NASDAQ:DNTH)

Rating:48Neutral
Price Target:
$20.00
▲( 8.58% Upside)
Dianthus Therapeutics faces significant challenges in achieving profitability and positive cash flow, despite revenue growth and a solid equity position. Technical indicators provide a neutral outlook, while valuation remains unattractive due to negative earnings.
Positive Factors
Clinical Trials
Initial topline data from the Phase II MaGic study is expected sooner than previously guided, indicating progress in the clinical trial timeline.
Financial Performance
Dianthus reported higher-than-expected license revenue and a smaller net loss than consensus estimates for 1Q25.
Product Development
DNTH103 has the potential to be a best-in-class complement inhibitor for generalized myasthenia gravis as a more convenient, self-administered treatment with no black box warning or REMS program.
Negative Factors
Market Sentiment
The short interest in Dianthus Therapeutics, Inc. is relatively high at 26.5% of the float.
Study Limitations
The study has the caveats of a small sample size and open-label study design.

Dianthus Therapeutics (DNTH) vs. SPDR S&P 500 ETF (SPY)

Dianthus Therapeutics Business Overview & Revenue Model

Company DescriptionDianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
How the Company Makes MoneyDianthus Therapeutics makes money through the development and commercialization of its proprietary monoclonal antibody therapies. Revenue streams include milestone payments and royalties from licensing agreements with larger pharmaceutical companies, as well as potential future sales of its therapeutic products upon regulatory approval. The company may also receive funding through research grants and partnerships with other biopharmaceutical firms aimed at advancing its clinical trials and expanding its pipeline of complement-targeting therapies.

Dianthus Therapeutics Financial Statement Overview

Summary
Dianthus Therapeutics shows revenue growth, but profitability and cash flow challenges persist. The company has a strong equity position with minimal debt, yet ongoing losses highlight the need for operational improvements.
Income Statement
45
Neutral
Dianthus Therapeutics shows significant revenue growth from 2023 to 2024, growing from $2.83 million to $6.24 million. However, the company remains unprofitable, with negative EBIT and net income, resulting in poor profit margins. The gross profit margin is strong at 100%, but this is offset by high operating losses.
Balance Sheet
55
Neutral
The company has a strong equity position with a high equity ratio, reflecting solid shareholder backing. The debt-to-equity ratio is low, indicating prudent leverage, but the negative stockholders' equity in prior years highlights potential financial instability.
Cash Flow
40
Negative
Free cash flow remains negative, and operating cash flow is insufficient to cover net income losses. The company relies heavily on financing activities for cash inflow, which could be a risk if external funding becomes less available.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
6.52M6.24M2.83M6.42M1.48M0.00
Gross Profit
5.17M5.82M2.47M6.27M-544.00K-1.98M
EBIT
-117.20M-101.86M-48.17M-29.70M-13.09M-78.70M
EBITDA
-117.00M-101.86M-48.17M-29.56M-13.09M-72.96M
Net Income Common Stockholders
-100.73M-84.97M-43.55M-28.48M-13.11M-74.94M
Balance SheetCash, Cash Equivalents and Short-Term Investments
263.23M275.24M173.72M75.49M7.64M148.84M
Total Assets
348.58M374.01M179.41M83.11M9.45M161.62M
Total Debt
1.40M1.49M585.00K788.00K0.000.00
Net Debt
-8.72M-21.30M-131.74M-14.58M-7.64M-58.15M
Total Liabilities
19.97M21.53M10.54M127.48M26.70M17.71M
Stockholders Equity
328.61M352.48M168.87M-44.37M-17.25M143.91M
Cash FlowFree Cash Flow
-78.10M-78.28M-36.97M-29.21M-9.94M-64.42M
Operating Cash Flow
-78.19M-78.18M-36.86M-29.07M-9.90M-64.02M
Investing Cash Flow
-316.22M-286.81M20.25M-59.82M-33.00K-10.63M
Financing Cash Flow
203.88M255.62M133.57M96.68M14.91M67.74M

Dianthus Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price18.42
Price Trends
50DMA
19.40
Negative
100DMA
20.97
Negative
200DMA
23.76
Negative
Market Momentum
MACD
-0.38
Positive
RSI
41.21
Neutral
STOCH
12.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Negative. The current price of 18.42 is below the 20-day moving average (MA) of 20.01, below the 50-day MA of 19.40, and below the 200-day MA of 23.76, indicating a bearish trend. The MACD of -0.38 indicates Positive momentum. The RSI at 41.21 is Neutral, neither overbought nor oversold. The STOCH value of 12.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DNTH.

Dianthus Therapeutics Risk Analysis

Dianthus Therapeutics disclosed 72 risk factors in its most recent earnings report. Dianthus Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Dianthus Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
$718.21M-6.33%23.92%-27.69%
55
Neutral
$639.97M-55.12%-60.26%
53
Neutral
$5.14B3.03-44.09%2.83%16.75%-0.06%
48
Neutral
$592.55M-28.73%189.31%51.03%
46
Neutral
$600.54M-343.83%387.20%21.00%
45
Neutral
$570.24M-150.50%-18.75%
45
Neutral
$738.73M-69.21%-13.76%57.73%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DNTH
Dianthus Therapeutics
18.42
-3.50
-15.97%
KALV
KalVista Pharmaceuticals
11.47
0.39
3.52%
ANAB
AnaptysBio
20.44
-2.92
-12.50%
TRVI
Trevi Therapeutics
6.29
3.73
145.70%
IMNM
Immunome
8.49
-6.13
-41.93%
PHAR
Pharming Group
10.38
1.33
14.70%

Dianthus Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Dianthus Therapeutics Announces Board Changes and Elections
Neutral
May 22, 2025

On May 22, 2025, Dianthus Therapeutics, Inc. announced the resignation of Leon O. Moulder, Jr. from its Board of Directors, with Simon Read, Ph.D., appointed as a new Class III director. Dr. Read will also join the Science and Technology Committee and the Nominating and Corporate Governance Committee, receiving compensation in line with the company’s Non-Employee Director Compensation Policy. The company also held its Annual Meeting of Stockholders on the same day, where Marino Garcia and Paula Soteropoulos were elected as Class I directors. Additionally, stockholders approved executive compensation and ratified Deloitte & Touche, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (DNTH) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.

Executive/Board Changes
Dianthus Therapeutics Appoints Sujay Kango to Board
Neutral
Mar 5, 2025

On March 4, 2025, Dianthus Therapeutics announced the resignation of Tomas Kiselak from its Board of Directors, which was not due to any disagreements with the company. The same day, Sujay Kango was appointed as a Class II director and a member of the Compensation Committee, receiving stock options and cash compensation in line with the company’s policies.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.